Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer-Reference-Cited by-同舟云学术

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Published:2018-11-07 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Niemeijer A. N.,Leung D.,Huisman M. C.,Bahce I.,Hoekstra O. S.,van Dongen G. A. M. S.,Boellaard R.,Du S.,Hayes W.,Smith R.,Windhorst A. D.^ORCID,Hendrikse N. H.,Poot A.,Vugts D. J.,Thunnissen E.,Morin P.,Lipovsek D.,Donnelly D. J.,Bonacorsi S. J.,Velasquez L. M.,de Gruijl T. D.^ORCID,Smit E. F.,de Langen A. J.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-07131-y.pdf

Reference24 articles.

1. Vokes, E. E. et al. Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann. Oncol. 29, 959–965 (2018).

2. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).

3. Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).

4. Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017).

5. Shukuya, T. & Carbone, D. P. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J. Thorac. Oncol. 11, 976–988 (2016).

Cited by 357 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New PET Tracers for Lymphoma;PET Clinics;2024-10

2. PD-L1 and PD-1 in immune regulation and their implications in blood cancers;Advances in Cancer Biology - Metastasis;2024-10

3. Prediction of programmed death-1 expression status in non–small cell lung cancer based on intratumoural and peritumoral computed tomography (CT) radiomics nomogram;Clinical Radiology;2024-09

4. Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models;Scientific Reports;2024-08-22

5. Radioimmunotheragnosis in Cancer Research;Cancers;2024-08-20